John Michael Dunn

This profile gathers the share dealings of John Michael Dunn across 3 companies, led by Biogen Inc., Immunic, Inc. and Acer Therapeutics Inc. In total, 102 filings cover trades dated from 18 May 2004 to 17 November 2023.

On the open market, the record shows 5 purchases worth €129k and 62 sales worth €6.1M. On balance, insiders were net sellers of €6.0M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 15 share grants and 14 option exercises.

The median purchase comes to €13k. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 100% of cases, with a median move of +24.9%. They describe history only and say nothing certain about the share price ahead.

On 20 November 2023 came the latest disclosure, a transaction in Acer Therapeutics Inc. The last insider purchase was made public on 28 July 2020, 2,294 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.